Europe

Brexit and the Falsified Medicines Directive

In order to help patients avoid being exposed to falsified medicines, the European Commission developed a series of measures to support patients in identifying licenced suppliers of pharmaceutical medicines, and suppliers to identify whether an end-user pack of medicines was genuine. The measures outlined in the Falsified Medicines Directive (2011/62/EU) have been applied across the European Union (EU), with […]

ETP in Europe: the case of UK, Estonia, Denmark, and Sweden

A report has just been published with cross-country comparison of implementations of electronic transmission of prescriptions: “European e-Prescriptions: Benefits and Success Factors”, by Ulrike Deetjen.

The report describes the economic, health, and societal benefits of e-prescriptions, within different policy structures. Based on previous evidence and expert interviews for case studies of Estonia, the United Kingdom, Denmark, and Sweden, it derives […]

A new study by colleagues at LSE, Alessandra Ferrario and Panos Kanavos:

Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden, Social Science & Medicine, Volume 124, January 2015, Pages 39-47,

Available at: http://www.sciencedirect.com/science/article/pii/S0277953614007266

The Innovative Medicines Initiative (IMI) is Europe’s largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients. The legislation establishing IMI 2 was approved by the EU Member States on 6 May 2014. IMI 2 will be launched later in 2014 and will run […]